稀美资源(09936)发布公告，于2025年9月19日(交易时段后)，公司与配售代理订立配售协议，据此，配 售代理已有条件同意担任公司的配售代理，以按竭诚基准促使不少于6名承配人按配售价每股配售股份 5.0港元认购最多2000万股配售股份。 配售事项所得款项净额估计约为9850万港元。公司拟将配售事项所得款项净额用作一般营运资金。 配售价每股配售股份5.0港元较股份于配售协议日期在联交所所报收市价每股5.90港元折让约15.25%。 假设已发行股份总数于本公告日期至完成日期期间并无变动，最多2000万股配售股份相当于经配发及发 行配售股份扩大后已发行股份总数约5.26%。 ...

Core Viewpoint - The company has entered into a placement agreement with a placement agent to issue up to 30.82 million shares at a price of HKD 0.43 per share, representing a discount of approximately 14.0% from the last closing price of HKD 0.50 on September 18, 2025 [1] Group 1: Placement Details - The placement will involve a maximum of 30.82 million shares, which will account for about 14.05% of the company's enlarged issued share capital [1] - The placement price of HKD 0.43 per share reflects a discount of approximately 14.0% compared to the last trading day's closing price [1] Group 2: Expected Proceeds and Utilization - If all placement shares are successfully placed, the company expects to raise approximately HKD 12.94 million in net proceeds [1] - The planned allocation of the proceeds includes 50% for the existing food business, 40% for the existing restaurant business, and 10% for general working capital [1]

Group 1 - The company announced a placement agreement with a placement agent to issue up to 30.82 million shares at a price of HKD 0.43 per share, representing approximately 14.05% of the enlarged issued share capital post-placement [1] - The placement price of HKD 0.43 per share reflects a discount of about 14.0% compared to the closing price of HKD 0.50 on the last trading day [1] - The estimated net proceeds from the placement, after deducting commissions and other expenses, are approximately HKD 12.94 million, with a net placement price of about HKD 0.42 per share [1] Group 2 - The company plans to allocate approximately 50% of the net proceeds to its existing food business, about 40% to its existing restaurant business, and 10% for general working capital [1]

假设于本公告日期至完成日期期间已发行股份数目并无变动，配售事项下的6800万股配售股份相当于本 公告日期现有已发行H股数目的约20.00%及现有已发行股份数目的约2.01%，以及经配发及发行配售股 份扩大后已发行H股数目的约16.67%及已发行股份数目的约1.97%。 假设所有配售股份均获悉数配售且待完成后，预计配售事项所得款项总额及所得款项净额(经扣除配售 事项佣金及配售事项的其他相关成本及开支后)将分别约为10.83亿港元及10.75亿港元。据此，每股股份 净发售价将约为15.81港元。 东方电气（600875）(01072)发布公告，于2025年9月18日(交易时段前)，公司与独家配售代理订立配售 协议，据此，独家配售代理已有条件同意作为公司独家配售代理按尽力基准促使不少于六名承配人(他 们及他们的最终实益拥有人将为独立第三方)购买6800万股配售股份，配售价为每股配售股份15.92港 元，相当于较2025年9月17日(即最后交易日)于香港联交所所报每股H股收市价17.30港元折让约7.98%。 ...

Group 1 - The company, 创胜集团-B (06628), announced that all conditions for the placement have been met and the completion of the placement occurred on September 17, 2025 [1] - A total of 14.4 million shares were successfully allocated to no less than six subscribers at a placement price of HKD 4.33 per share [1] - The net proceeds from the placement amount to approximately HKD 59.34 million [1]

Group 1 - The core point of the article is that Ying Sheng Science (00209) has engaged in a share placement agreement, raising approximately HKD 10.83 million through the issuance of new shares at a price of HKD 0.350 per share [1] - On September 16, shareholders transferred shares worth HKD 3.7261 million from Hope Securities to Bank of China (Hong Kong), representing 8.45% of the total shares [1] - The share placement involves issuing 30.9515 million new shares, which accounts for about 16.67% of the company's total issued shares post-placement [1] Group 2 - The estimated net proceeds from the placement, after deducting all related expenses, are approximately HKD 10.32 million [1] - The company plans to allocate around 50% of the net proceeds for loan repayment and the other 50% for operational funds and general corporate purposes [1]

Core Viewpoint - Clinique Holdings (08367.HK) announced a placement agreement on September 12, 2025, to issue up to 13.8 million new shares at a price of HKD 0.180 per share, representing a discount of approximately 16.67% compared to the closing price of HKD 0.216 on the same day [1] Group 1 - The placement will be conducted through a placement agent on a best-efforts basis [1] - The net proceeds from the placement, estimated at approximately HKD 2.43 million, will be used for general working capital of the group [1]

Core Viewpoint - Clinique Holdings (08367) announced a placement agreement to issue up to 13.8 million new shares at a price of HKD 0.180 per share, representing a discount of approximately 16.67% from the closing price of HKD 0.216 on September 12, 2025 [1] Summary by Relevant Sections - **Placement Details** - The maximum number of shares to be placed is 13.8 million, which accounts for about 19.99% of the company's total issued share capital of 69.05 million shares as of the announcement date [1] - The net proceeds from the placement are estimated to be approximately HKD 2.43 million, assuming full placement and after deducting all related expenses [1] - **Purpose of the Placement** - The board believes that the placement is a good opportunity to expand the shareholder base and capital base, as well as to raise funds for the group's working capital needs [1] - The terms of the placement agreement are considered fair and reasonable, aligning with the overall interests of the group and its shareholders [1]

Group 1 - The company, Ying Sheng Science (00209), announced a placement agreement with a placement agent to issue 30.9515 million new shares at a price of HKD 0.350 per share, representing approximately 16.67% of the company's total issued shares post-placement [1] - The placement price of HKD 0.350 per share is at a premium of about 1.45% compared to the closing price of HKD 0.345 per share on the date of the placement agreement [1] - The total nominal value of the placement shares will be HKD 30.95 million, with total proceeds estimated at HKD 10.833 million, and the net proceeds after all related expenses are expected to be approximately HKD 10.32 million [1] Group 2 - Approximately 50% of the net proceeds will be used to repay loans, while the remaining 50% will be allocated for the group's working capital and general corporate purposes [1]

格隆汇9月11日丨瀛晟科学(00209.HK)公告，于2025年9月11日，公司与配售代理订立配售协议，据此， 配售代理同意按悉数包销基准按每股配售股份0.350港元之价格为及代表公司向不少于六名承配人配售 3095.15万股新股份。配售股份将根据一般授权配发及发行。配售价每股配售股份0.350港元较：(i)于配 售协议日期在联交所所报之收市价每股股份0.345港元溢价约1.45%；及(ii)于紧接配售协议日期前五个 连续交易日在联交所所报每股股份之平均收市价0.377港元折让约7.16%。假设于本公告日期与配售事项 完成之间，公司已发行股本将不会发生变动，配售事项项下之3095.15万股新股份占于本公告日期公司 现有已发行股份总数的20%，及占经配售事项扩大后公司已发行股份总数约16.67%。配售股份之总面值 将为30.95万港元。配售事项之所得款项总额将为1083.3万港元。经扣除所有相关开支后，配售事项之所 得款项净额估计约为1032万港元，其(i)约50%拟用作偿还贷款，及(ii)约50%拟用作本集团营运资金及一 般企业用途。 ...